Literature DB >> 19514014

The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease.

Paolo Barone1, Angelo Antonini, Carlo Colosimo, Roberto Marconi, Letterio Morgante, Tania P Avarello, Eugenio Bottacchi, Antonino Cannas, Gabriella Ceravolo, Roberto Ceravolo, Giulio Cicarelli, Roberto M Gaglio, Rosa M Giglia, Francesco Iemolo, Michela Manfredi, Giuseppe Meco, Alessandra Nicoletti, Massimo Pederzoli, Alfredo Petrone, Antonio Pisani, Francesco E Pontieri, Rocco Quatrale, Silvia Ramat, Rosanna Scala, Giuseppe Volpe, Salvatore Zappulla, Anna Rita Bentivoglio, Fabrizio Stocchi, Giorgio Trianni, Paolo Del Dotto.   

Abstract

We performed a multicenter survey using a semistructured interview in 1,072 consecutive patients with Parkinson's disease (PD) enrolled during 12 months in 55 Italian centers to assess the prevalence of nonmotor symptoms (NMSs), their association with cognitive impairment, and the impact on patients' quality of life (QoL). We found that 98.6% of patients with PD reported the presence of NMSs. The most common were as follows: fatigue (58%), anxiety (56%), leg pain (38%), insomnia (37%), urgency and nocturia (35%), drooling of saliva and difficulties in maintaining concentration (31%). The mean number of NMS per patient was 7.8 (range, 0-32). NMS in the psychiatric domain were the most frequent (67%). Frequency of NMS increased along with the disease duration and severity. Patients with cognitive impairment reported more frequently apathy, attention/memory deficit, and psychiatric symptoms. Apathy was the symptom associated with worse PDQ-39 score but also presence of fatigue, attention/memory, and psychiatric symptoms had a negative impact on QoL. These findings further support a key role for NMS in the clinical frame of PD and the need to address them specifically in clinical trials using dedicated scales. 2009 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19514014     DOI: 10.1002/mds.22643

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  371 in total

1.  Epidemiology and clinical phenomenology for Parkinson's disease with pain and fatigue.

Authors:  Hong-Bo Wen; Zhen-Xin Zhang; Han Wang; Ling Li; Honglei Chen; Yiming Liu; Baorong Zhang; Qun Xu
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

Review 2.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

3.  Tolcapone addition improves Parkinson's disease associated nonmotor symptoms.

Authors:  Thomas Müller
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

4.  Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire.

Authors:  David Crosiers; Barbara Pickut; Jessie Theuns; Peter Paul De Deyn; Christine Van Broeckhoven; Pablo Martinez-Martin; K Ray Chaudhuri; Patrick Cras
Journal:  Am J Neurodegener Dis       Date:  2012-07-23

Review 5.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

6.  Patient-centered integrated healthcare improves quality of life in Parkinson's disease patients: a randomized controlled trial.

Authors:  Carsten Eggers; R Dano; J Schill; G R Fink; M Hellmich; L Timmermann
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

Review 7.  [Depression and neurological diseases].

Authors:  D Piber; K Hinkelmann; S M Gold; C Heesen; C Spitzer; M Endres; C Otte
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

Review 8.  Treatment of Sleep Dysfunction in Parkinson's Disease.

Authors:  Amy W Amara; Lana M Chahine; Aleksandar Videnovic
Journal:  Curr Treat Options Neurol       Date:  2017-07       Impact factor: 3.598

Review 9.  Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.

Authors:  Thomas Müller; Paul Foley
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

10.  Self-Reported Symptoms of Parkinson's Disease by Sex and Disease Duration.

Authors:  Ju Young Shin; Ryan T Pohlig; Barbara Habermann
Journal:  West J Nurs Res       Date:  2016-09-23       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.